Get the Stockscreener App
24.02
0.89%
-0.215
After Hours:
24.00
-0.015
-0.06%
Janux Therapeutics Inc stock is traded at $24.02, with a volume of 927.78K.
It is down -0.89% in the last 24 hours and up +3.96% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$24.23
Open:
$23.79
24h Volume:
927.78K
Relative Volume:
1.02
Market Cap:
$1.42B
Revenue:
$13.05M
Net Income/Loss:
$-60.54M
P/E Ratio:
-20.70
EPS:
-1.16
Net Cash Flow:
$-37.82M
1W Performance:
-7.53%
1M Performance:
+3.96%
6M Performance:
-44.77%
1Y Performance:
-40.85%
1-Day Range:
$23.54
$24.45
1-Week Range:
$23.54
$26.90
52-Week Range:
$22.48
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
24.02 | 1.43B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
Why Janux Therapeutics Inc. stock attracts strong analyst attentionTriple Return Setup With Risk Control Explained - metal.it
What makes Janux Therapeutics Inc. stock price move sharplyDaily Stock Market Swing Alerts Highlight Key Movers - beatles.ru
Why did JANX's operating expenses surge in Q3 2024? - AInvest
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification - TipRanks
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
Is Janux Therapeutics Inc. a growth stock or a value stockStay informed with daily expert analysis - jammulinksnews.com
Combining machine learning predictions for Janux Therapeutics Inc. Yield Curve Outlook and Long-Term Implication Summary - metal.it
What are analysts’ price targets for Janux Therapeutics Inc. in the next 12 monthsTremendous portfolio expansion - jammulinksnews.com
What are the latest earnings results for Janux Therapeutics Inc.Accelerated financial growth - jammulinksnews.com
Is Janux Therapeutics Inc. stock overvalued or undervaluedExponential return rates - jammulinksnews.com
How does Janux Therapeutics Inc. generate profit in a changing economyUnprecedented profit potential - jammulinksnews.com
Evercore ISI Analyst Maintains Buy Rating on Janux Therapeutics with $25.00 Price Target - AInvest
Janux Therapeutics Inc: Strategic Advancements and Strong Positioning in Oncology Drive Buy Rating - TipRanks
Adc Therapeutics Sa shares fall 1.83% after-hours following Janux Therapeutics' R&D Day press release. - AInvest
Janux Therapeutics Inc. Stock Analysis and ForecastConsistent triple-digit returns - PrintWeekIndia
Why Intel Stock Is Plummeting Today - The Globe and Mail
What makes Janux Therapeutics Inc. stock attractive to long term investorsRapid-fire capital growth - jammulinksnews.com
Janux Therapeutics’ Strategic Expansion and Promising Pipeline Drive Buy Rating - TipRanks
Janux Therapeutics Faces Trade Policy Challenges: Impact on Operations and Growth - TipRanks
Innovative Preclinical Programs and Strategic Tumor Activation Drive Buy Rating for Janux Therapeutics - TipRanks
What analysts say about Janux Therapeutics Inc. stockStrongest growth potential - PrintWeekIndia
Is Janux Therapeutics Inc. stock a growth or value playHigh-profit capital plays - jammulinksnews.com
What drives Janux Therapeutics Inc. stock priceOutstanding capital appreciation - Autocar Professional
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day - Yahoo Finance
Top Stocks Powering the Fourth Industrial Revolution - The Globe and Mail
Is Janux Therapeutics Inc. a good long term investmentFree Predictions - Autocar Professional
Why RTX Stock Is Down Today - The Globe and Mail
Janux Therapeutics Receives Buy Rating from Leerink Partners Amid Strategic Initiatives and Long-Term Growth Potential - AInvest
Strategic Initiatives and Long-Term Potential Drive Buy Rating for Janux Therapeutics Inc. - TipRanks
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):